Baird Medical Showcases Advanced MWA Technology with UCSF Expert in Guangzhou and Shenzhen

NEW YORK, April 2, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company") proudly hosted Dr. Quan-Yang Duh, a world-renowned endocrine surgeon and Chief of Endocrine Surgery at the University of California, San Francisco (UCSF), for an in-depth clinical observation visit in Guangzhou and Shenzhen, China. During his visit, Dr. Duh closely examined the real-world application of Baird Medical's advanced microwave ablation (MWA) technology.

In Guangzhou, Dr. Duh visited several prestigious hospitals, where he observed a range of thyroid ablation cases. One particularly notable case involved a patient with bilateral thyroid nodules, including a 4 cm lesion, successfully treated using Baird Medical's MWA system. The procedure, performed by Dr. Feng Han, a leading MWA specialist at Sun Yat-sen University Cancer Center, was executed with remarkable precision and efficiency. The patient remained fully awake and comfortable throughout underscoring the minimally invasive nature of the procedure.

"The case was highly educational," said Dr. Duh. "Dr. Han demonstrated exceptional expertise, and the speed and accuracy of the procedure highlight both the skill of the medical team and the medical team and the sophistication of the technology." Following the procedure, Dr. Duh engaged in in-depth academic discussions with Dr. Feng Han and Dr. Jian Hua Zhou, Chief of Interventional Radiology at Sun Yat-sen University Cancer Center, further fostering international collaboration in thyroid ablation advancements.

Dr. Duh continued his visit in Shenzhen, where he observed additional MWA procedures at one of the city's leading thyroid hospitals. He also participated in academic discussions with top specialists in the field and delivered a presentation titled "Advances in Surgical Management of Thyroid and Parathyroid Diseases." His talk provided valuable insights into the latest developments in endocrine surgery and facilitated an in-depth exchange on the growing role of microwave ablation in thyroid treatment, particularly its integration with surgical approaches.

"We are honored to facilitate these global academic exchanges and showcase the clinical impact of our MWA technology," said Haimei Wu, Chairwoman of Baird Medical. "As we continue to expand, we remain committed to driving innovation and working alongside top-tier medical professionals to enhance the accessibility and precision of minimally invasive thyroid treatments."

As Baird Medical continues its global expansion, the Company remains dedicated to pioneering advancements in microwave ablation technology and forging strategic partnerships that redefine the future of thyroid care.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Eric Huang, PR Liaison

Baird Medical Investment Holdings Ltd.

Phone: +1 (888) 508-6228

Email: [email protected]

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-advanced-mwa-technology-with-ucsf-expert-in-guangzhou-and-shenzhen-302418226.html

SOURCE BDMD